keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasys

keyword
https://www.readbyqxmd.com/read/29334503/family-history-of-autoimmune-diseases-and-risk-of-gastric-cancer-a-national-cohort-study
#1
Jianguang Ji, Jan Sundquist, Kristina Sundquist
A personal history of autoimmune diseases is associated with an increased incidence of gastric cancer, but whether they share familial susceptibility is still unknown. The contribution of shared environmental or genetic factors toward the observed familial aggregation has not been determined. We used a few Swedish registers, including the Swedish Multigeneration Register and the Cancer Register, to examine the familial risk of gastric cancer among individuals with a family history of a set of autoimmune diseases...
January 12, 2018: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/29334280/comparison-of-guidelines-for-the-use-of-tnf-inhibitors-for-psoriasis-in-the-united-states-canada-europe-and-the-united-kingdom-a-critical-appraisal-and-comprehensive-review
#2
Vidhi V Shah, Erica B Lee, Shivani Reddy, Elaine J Lin, Jashin J Wu
PURPOSE: To compare and contrast evidence-based CPGs from leading dermatological organizations for the use of tumor necrosis factor inhibitors (TNFi) in psoriasis. MATERIALS AND METHODS: Guidelines from the British National Institute for Health and Care Excellence (NICE), the British Association of Dermatologists (BAD), the American Academy of Dermatology (AAD), the National Psoriasis Foundation (NPF), and the Canadian Dermatology Association (CDA) were reviewed and compared...
January 15, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29334270/secukinumab-in-multi-failure-psoriatic-patients-the-last-hope
#3
M Magnano, C Loi, A Patrizi, P Sgubbi, R Balestri, G Rech, L Tasin, C R Girardelli, A Conti, G Odorici, A Campanati, A M Offidani, F Bardazzi
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent, and, in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also those agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, recently approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis...
January 15, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29334162/prevalence-of-metabolic-syndrome-in-children-with-moderate-to-severe-psoriasis-treated-with-tnf-inhibitors-in-comparison-to-conventional-agents
#4
Nawaf Al Mutairi, Dhuha Alrqobah, Nasser Haji Hussain
Association of childhood psoriasis with metabolic syndrome has not been studied well. TNF-alfa contributes to the inflammation seen in metabolic syndrome, and recently etanercept has shown to reduce the levels of inflammatory markers. Assessment of prevalence of metabolic syndrome in juvenile psoriasis patients in Kuwait. We included 236 patients with moderate to severe psoriasis below 18 years treated for at least 24 weeks with TNF inhibitors (Group A), and equal number of age and sex matched cases treated with conventional medications (Group B)...
January 15, 2018: Dermatologic Therapy
https://www.readbyqxmd.com/read/29333670/pustular-psoriasis-and-related-pustular-skin-diseases
#5
REVIEW
H Bachelez
Patients with pustular psoriasis or related pustular diseases may have genetic abnormalities impairing the function of key players of the innate skin immune system. Recently, identification of these abnormalities has changed the paradigm of several of these diseases. These include generalized pustular psoriasis, palmoplantar pustular psoriasis and acrodermatitis continua of Hallopeau, and also drug-induced acute exanthematous generalized pustular eruption. Identified mutations in IL36RN, CARD14 and AP1S3 in different groups of patients lead to enhanced inflammatory cascade in several cellular subtypes including keratinocytes, and to the recruitment and activation of neutrophils and macrophages...
January 15, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29333662/serum-levels-of-psoriasin-s100a7-and-koebnerisin-s100a15-as-potential-markers-of-atherosclerosis-in-patients-with-psoriasis
#6
S M Awad, D A Attallah, R H Salama, A M Mahran, E Abu El-Hamed
BACKGROUND: Psoriasin (S100A7) and koebnerisin (S100A15) are proinflammatory proteins upregulated in psoriasis, but their relation to atherosclerosis remains unclear. AIM: To evaluate the role of serum psoriasin and koebnerisin as possible markers for subclinical atherosclerosis in patients with psoriasis. METHODS: Serum levels of psoriasin and koebnerisin were measured by ELISA in 45 patients with psoriasis and in 45 healthy controls (HCs)...
January 14, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29332713/fissured-tongue-in-patients-with-psoriasis
#7
Bruna Lavinas Sayed Picciani, Thays Teixeira-Souza, Thiago Moreira Pessôa, Lívia Maria Santos Izahias, Jane Marcy Neffa Pinto, David Rubem Azulay, João Carlos Regazzi Avelleira, Sueli Carneiro, Eliane Pedra Dias
No abstract text is available yet for this article.
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29332708/management-of-psoriasis-in-patients-with-inflammatory-bowel-disease-from-the-medical-board-of-the-national-psoriasis-foundation
#8
REVIEW
Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees
BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017...
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29332640/cognitive-impairment-in-patients-with-psoriasis-a-matched-case-control-study
#9
Marco Innamorati, Rossella M Quinto, David Lester, Luca Iani, Dario Graceffa, Claudio Bonifati
BACKGROUND: In the past decade, a few studies have suggested that psoriasis could be associated with the presence of mild cognitive deficits. OBJECTIVES: The aim of the present matched case-control study was to investigate several cognitive domains (executive functions, verbal memory, attention, and language) in a sample of outpatients with psoriasis. We also investigated whether cognitive impairment was associated with poor health-related quality of life (HRQoL) in patients with psoriasis...
February 2018: Journal of Psychosomatic Research
https://www.readbyqxmd.com/read/29332378/role-of-psoriasis-on-subclinical-cardiovascular-disease
#10
Luca DI Vito, Damiano Abeni, Claudia Uras, Alessandra Magenta, Roberta Ciarapica, Maurizio C Capogrossi, Guido Melillo
No abstract text is available yet for this article.
January 11, 2018: Minerva Medica
https://www.readbyqxmd.com/read/29332301/evaluating-risk-tolerance-from-a-systematic-review-of-preferences-the-case-of-patients-with-psoriasis
#11
REVIEW
Juan Marcos Gonzalez
BACKGROUND: Stated-preference methods have been widely used to evaluate patient-relative preferences for the benefits and potential harms of psoriasis treatments. However, risk tolerance measures for treatment-related harms, a corollary of preferences, are rare despite their critical role in shared decision making and regulatory benefit-risk evaluations. This article presents a method to enhance information on patient risk tolerance through previously published preference results. OBJECTIVE: The objective of this article was to conduct the first meta-analysis of preferences to characterize the distribution of patients' maximum acceptable risk of harms associated with psoriasis treatments...
January 13, 2018: Patient
https://www.readbyqxmd.com/read/29331748/safety-and-efficacy-of-anti-programmed-death-1-antibodies-in-patients-with-cancer-and-pre-existing-autoimmune-or-inflammatory-disease
#12
François-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, Jean-Marie Michot, Emilie Routier, Laurent Taillade, Stéphane Champiat, Sandrine Aspeslagh, Julien Haroche, Laurence Albiges, Christophe Massard, Nicolas Girard, Stéphane Dalle, Benjamin Besse, Salim Laghouati, Jean-Charles Soria, Christine Mateus, Caroline Robert, Emilie Lanoy, Aurélien Marabelle, Olivier Lambotte
OBJECTIVE: Patients with autoimmune or inflammatory disease (AID) are susceptible to immune-related adverse events (irAEs) when treated with immune check-point inhibitors (ICIs). We decided to analyse the safety and effectiveness of anti-PD-1 antibodies in AID patients and look for an association between the presence of pre-existing AID and the clinical outcome. METHODS: In a prospective study of the REISAMIC registry of grade ≥2 irAEs occurring in ICI-treated patients, we studied the associations between pre-existing AID on one hand and irAE-free survival, overall survival and best objective response rate on the other...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29330859/differential-effects-of-phototherapy-adalimumab-and-betamethasone-calcipotriol-on-effector-and-regulatory-t-cells-in-psoriasis
#13
I S Kotb, B J Lewis, R N Barker, A D Ormerod
BACKGROUND: Psoriasis is a chronic T cell-mediated skin disease with marked social and economic burdens. Current treatments are unsatisfactory, with unpredictable remission times and incompletely understood modes of action. Recent advances in our understanding of the pathogenesis of psoriasis identify the imbalance between CD4+ T effector cells, particularly the T helper (Th) 17 subset, and regulatory T cells (Treg) as key to the development of psoriatic lesions, and therefore a novel therapeutic target...
January 12, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29330579/-initially-undetected-de-novo-psoriasis-triggered-by-nivolumab-for-metastatic-base-of-the-tongue-carcinoma
#14
S Troyanova-Slavkova, L Eickenscheidt, K Dumann, L Kowalzick
Nivolumab is a monoclonal antibody that binds to the PD-1 receptor on T cells and inhibits the interaction with the PD-L1 and PD-L2 ligands on cancer cells. Thus, nivolumab has immunostimulatory properties. The known side effects of this therapy include fatigue, skin rash, dysfunction of the thyroid gland and colitis, which are explained by the immunoregulatory mechanisms of the drug. Here we report on the case of a 58-year-old man with metastatic base of tongue carcinoma who developed de novo psoriasis triggered by nivolumab...
January 12, 2018: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29330560/altered-bone-remodeling-in-psoriatic-disease-new-insights-and-future-directions
#15
REVIEW
Ananta Paine, Christopher Ritchlin
Psoriatic arthritis (PsA) is an inflammatory rheumatic disorder that occurs in patients with psoriasis and predominantly affects musculoskeletal structures, skin, and nails. The etiology of PsA is not well understood but evidence supports an interplay of genetic, immunologic, and environmental factors which promote pathological bone remodeling and joint damage in PsA. Localized and systemic bone loss due to increased activity of osteoclasts is well established in PsA based on animal models and translational studies...
January 12, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29329927/systems-biomarkers-in-psoriasis-integrative-evaluation-of-computational-and-experimental-data-at-transcript-and-protein-levels
#16
Tuba Sevimoglu, Beste Turanli, Ceyhun Bereketoglu, Kazim Yalcin Arga, Ayse Serap Karadag
Psoriasis is a complex autoimmune disease with multiple genes and proteins being involved in its pathogenesis. Despite the efforts performed to understand mechanisms of psoriasis pathogenesis and to identify diagnostic and prognostic targets, disease-specific and effective biomarkers were still not available. This study is compiled regarding clinical validation of computationally proposed biomarkers at gene and protein expression levels through qRT-PCR and ELISA techniques using skin biopsies and blood plasma...
January 9, 2018: Gene
https://www.readbyqxmd.com/read/29328510/a-multidimensional-assessment-of-the-burden-of-psoriasis-results-from-a-multinational-dermatologist-and-patient-survey
#17
C E M Griffiths, S J Jo, L Naldi, R Romiti, E Guevara-Sangines, T Howe, G Pietri, I Gilloteau, C Richardson, H Tian, M Augustin
BACKGROUND: Psoriasis is a chronic, immune-mediated disease, characterised by symptoms that include itching and skin pain and is often associated with comorbidities. Patients have a substantial detriment to quality of life (QoL) and work productivity with associated cost burden. OBJECTIVE: To investigate the incremental burden of comorbidities, itch, and affected body areas among systemic eligible patients with psoriasis, using a multinational survey of dermatologists and their psoriasis patients...
January 12, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29328507/genetics-of-immune-mediated-inflammatory-diseases
#18
REVIEW
Trixy David, Stephanie Ling, Anne Barton
Immune-mediated inflammatory diseases (IMIDs) are characterised by dysregulation of the normal immune response, which leads to inflammation. Together, they account for a high disease burden in the population, given that they are usually chronic conditions with associated co-morbidities. Examples include systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease and type 1 diabetes. Since the advent of genome-wide association studies, evidence of considerable genetic overlap in the loci predisposing to a wide range of IMIDs has emerged...
January 12, 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29327643/adherence-to-biologics-in-patients-with-psoriasis
#19
Lauren Seale, Leah A Cardwell, Steven R Feldman
Psoriasis has a profound impact on patients' lives, but adherence to topical treatment of psoriasis is still poor. Biologic treatment has revolutionized the management of psoriasis, but adherence to treatment may still be a barrier for some patients. Areas covered: A PubMed search was conducted in August 2017 using the terms "biologics psoriasis adherence" and "biologics psoriasis survival." Additional articles were obtained by perusing the references of articles identified in the original PubMed search. Articles that did not specifically mention "survival," "adherence," or "persistence" were not included...
January 12, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29327456/discovery-and-characterization-of-cd12681-a-potent-ror%C3%AE-inverse-agonist-preclinical-candidate-for-the-topical-treatment-of-psoriasis
#20
Gilles Ouvry, Nicolas Atrux-Tallau, Franck Bihl, Aline Bondu, Claire Bouix-Peter, Isabelle Carlavan, Olivier Christin, Marie-Josée Cuadrado, Claire Defoin-Platel, Sophie Deret, Denis Duvert, Christophe Feret, Mathieu Forissier, Jean-François Fournier, David Froude, Fériel Hacini-Rachinel, Craig Steven Harris, Catherine Hervouet, Hélène Huguet, Guillaume Lafitte, Anne-Pascale Luzy, Branislav Musicki, Danielle Orfila, Benjamin Ozello, Coralie Pascau, Jonathan Pascau, Véronique Parnet, Guillaume Peluchon, Romain Pierre, David Piwnica, Catherine Raffin, Patricia Rossio, Delphine Spiesse, Nathalie Taquet, Etienne Thoreau, Rodolphe Vatinel, Emmanuel Vial, Laurent François Hennequin
With possible implications in multiple autoimmune diseases, the retinoic acid receptor-related orphan receptor RORγ has become a very sought-after target in the pharmaceutical industry. Herein are described the efforts to identify a potent RORγ inverse agonist compatible with topical application for the treatment of skin diseases. These efforts culminated with the discovery of CD12681 (compound 14; N-(2,4-dimethylphenyl)-N-isobutyl-2-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide), a potent inverse agonist with in vivo activity in an IL-23 induced skin inflammation model in mouse...
January 12, 2018: ChemMedChem
keyword
keyword
43199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"